Perfint Healthcare Corporation launches MAXIO, an innovative intelligent ablation tool

Top Quote Perfint Healthcare Corporation, based in Chennai, India and U.S.A., today announced the launch of MAXIO, the company's integrated planning, navigation and robotic targeting system for CT Guided tumor ablation. End Quote
  • (1888PressRelease) June 05, 2012 - The ground-breaking product was unvieled by Mr Sam Pitroda, Chairman National Innovation Council and Advisor to the Prime Minister on Public Information Infrastructure and Innovation, at a gala event at the Oberoi in New Delhi on Saturday, 2 June where doctors gathered from across the country to witness the birth of this exciting product.

    Commenting on his company's latest innovation, Nandakumar Subburaman, CEO and founder of Perfint stated, "Interventional Oncology and in specific Tumor Ablation is rapidly becoming an effective alternate to surgical treatment for cancer, globally. MAXIO brings the practice of Interventional Oncology to a whole new level." He added, "Our goal was to create a solution that would make life-saving ablation procedures available to a greater number of cancer sufferers. To do that, we realized that the complex techniques used by interventional radiologists would have to be made simpler and more predictable. That's what we've done with MAXIO".

    " Tumor ablation is an effective alternate to surgery for inoperable tumors. For example, only about 20% of the liver cancer patients are surgical candidates. Tumor Ablation is an image guided minimally invasive procedure in which devices such as needles are used to deliver thermal or other energy to destroy the tumor. Visualization, planning and needle placement are key to successful tumor ablation. MAXIO helps clinicians visualize, plan and perform tumor ablation safely with consistent quality. said Guruswamy K, Director - New Products, Perfint Healthcare.

    "MAXIO, developed through support under the BIPP scheme of the Department of Biotechnology, meets the best-in-class standards globally. The product complies with CE marking requirements and over the next few months we would be obtaining regulatory approvals to sell in most global markets including in the USA. Our R&D teams in India and the USA work closely with expert clinicians across the world to continuously introduce features on the MAXIO platform" said Gnanasekar V, GM - Advanced Technologies.

    " MAXIO's workflow and Robotic targeting will make it easy for large scale adoption of tumor ablation in highly populous societies such as in India, China, Indonesia and Latin America - where there is an urgent need to create high quality cancer care infrastructure, quickly and at a low cost. And in clinically advanced societies like in the USA, EU, Japan or Korea where Tumor Ablation is already quite common, we believe the experts will use MAXIO helpful to address tricky tumors and to improve clinical productivity. We are looking to revolutionize tumor ablation" said Bala - Director, Global Sales and Customer Support.

    MAXIO combines Tumor visualisation in 3D and procedure planning with Robotic targeting that helps clinicians achieve consistent procedure quality. During the planning phase, clinicians can "see" the tumor and surrounding structures, determine the best approach to reach the tumor, select the appropriate number and type of energy probes, visualise estimated ablation volumes and determine the sequence of probe placement.
    MAXIO's robotic targeting system then helps the clinician advance the probes as planned, to reach the tumor safely. Once the ablation procedure has been performed, MAXIO's visualization tools help clinicians to verify and extend the procedure if needed.

    Perfint's launch event was followed by hands-on workshops and lectures by expert Interventional Radiologists from around the world on Sunday.

    "This launch is just one of many major milestones for the company over the past several years, as they progress toward their goal of being a $100M company by 2015. We couldn't be more excited about MAXIO." stated Don Alvarez, Perfint's Director of Global Product Marketing. "We feel it's the right product, at the right time. And to launch it here, in Delhi, is evidence of Perfint's commitment to Emerging Societies." Perfint has been successfully selling their other targeting products (ROBIO and PIGA CT) to many of the best hospitals throughout India, South Asia, West Asia, APACA and Russia, and is making inroads into Latin America, South Africa and EU.

    About Perfint Healthcare

    Perfint Healthcare is an innovative medical device company focused on the development of robotic assisted technologies that simplify complex procedures and improve the standard of care provided to patients in need of interventional therapies.

    Our line of robotic positioning systems (PIGA CT, ROBIO and MAXIO) provide clinicians with a safer, easier and more effective way to perform a full range of diagnostic and therapeutic procedures including ablation, biopsy, pain management, fine needle aspiration and drug delivery.

    Perfint Healthcare is led by a leadership team which boasts more than 100 years of cumulative experience in healthcare technology and management, under the guidance of some of the most respected names in interventional oncology.

  • FB Icon Twitter Icon In-Icon
Contact Information